IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Roudy who wrote ()	4/23/1999 10:45:00 AM
From: Roudy	Read Replies (1) of 1762

Posting from the Yahoo thread. Anyone have an insight on the manufacturing of Bexxar? IDEC's Future . . . by: DavidSage 700 of 700... looks very strong. Rituxan sales (read:profits) are growing beyond expectations, look for increased off-label use in '99 and '00. Y-2B8 is gaining on Coulter's Bexxar, as that company struggles with manufacturing and FDA (hurdles IDPH has already passed). Further, Y-2B8 profile (production, distribution, administration, effects, etc.) is favorable to Bexxar's. IDEC's pipeline and platform technology should sustain growth for years. Technically, the stock is digesting the recent run-up and has support around 45, resistance at 59. With ASCO in May, expect a pop to new highs within a couple of weeks. Breaking 70 and holding above 60 for a few months should lead to a stock split. Nice work patient longs, the fun and profits will continue...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next